Background: Globally, most countries have implemented a test-and-treat policy to reduce morbidity and mortality associated with HIV infection. However, the impact of this strategy has not been critically appraised in many settings, including Zambia. We evaluated the retention and clinical outcomes of adults enrolled in antiretroviral therapy (ART) and assessed the impact of the test-and-treat policy.

Methods: We conducted a retrospective cohort study among 6,640 individuals who initiated ART between January 1, 2014 and July 31, 2016 [before test-and-treat cohort (BTT),  = 2,991] and between August 1, 2016 and October 1, 2020 [after test-and-treat cohort (ATT),  = 3,649] in 12 districts of the Southern province. To assess factors associated with retention, we used logistic regression (xtlogit model).

Results: The median age [interquartile range (IQR)] was 34.8 years (28.0, 42.1), and 60.2% ( = 3,995) were women. The overall retention was 83.4% [95% confidence interval (CI) 82.6, 84.4], and it was significantly higher among the ATT cohort, 90.6 vs. 74.8%,  < 0.001. The reasons for attrition were higher in the BTT compared to the ATT cohorts: stopped treatment (0.3 vs. 0.1%), transferred out (9.3 vs. 3.2%), lost to follow-up (13.5 vs. 5.9%), and death (1.4 vs. 0.2%). Retention in care was significantly associated with the ATT cohort, increasing age and baseline body mass index (BMI), rural residence, and WHO stage 2, while non-retention was associated with never being married, divorced, and being in WHO stage 3.

Conclusion: The retention rate and attrition factors improved in the ATT compared to the BTT cohorts. Drivers of retention were test-and-treat policy, older age, high BMI, rural residence, marital status, and WHO stage 1. Therefore, there is need for interventions targeting young people, urban residents, non-married people, and those in the symptomatic WHO stages and with low BMI. Our findings highlight improved ART retention after the implementation of the test-and-treat policy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600392PMC
http://dx.doi.org/10.3389/fpubh.2023.1244125DOI Listing

Publication Analysis

Top Keywords

test-and-treat policy
8
clinical outcomes
8
southern province
8
retrospective cohort
8
cohort study
8
test-and-treat cohort
8
cohort
5
hiv test-and-treat
4
policy improves
4
improves clinical
4

Similar Publications

Introduction: Urgent, tailored and equitable action is needed to address the alarming rise in syphilis rates in Canada. In the last decade, the rates of infectious syphilis have increased by 345% in Ontario, Canada. Underserved populations-people who use drugs, un(der)housed individuals and those living in rural and remote areas-face unique social and healthcare challenges that increase their vulnerability to syphilis infections and hinder their access to timely diagnosis and treatment.

View Article and Find Full Text PDF

Background: We previously published a systematic review evaluating retention in care after antiretroviral therapy treatment initiation among adults in low- and middle-income countries. We estimated retention at 36 months to be at 74% for studies published from 2008-2013. This review evaluates retention after the implementation of Universal Test and Treat in 2015.

View Article and Find Full Text PDF

Monitoring for advanced disease in the universal test and treat era: trends in CD4 count testing in South Africa.

BMC Glob Public Health

January 2025

Health Economics and Epidemiology Research Office, Department of Internal Medicine, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.

Article Synopsis
  • Under South Africa's Universal Test and Treat (UTT) policy, CD4 counts are no longer mandatory for HIV treatment eligibility, but they still serve as an important indicator of disease progression.
  • An analysis of CD4 testing data from various South African provinces showed that overall first CD4 tests had increased slightly after the UTT policy was implemented, despite a previous decline in testing numbers.
  • The study found no significant decline in CD4 testing volumes at patient presentation since the UTT policy began, differing from trends observed in other resource-limited settings that depend heavily on external funding.
View Article and Find Full Text PDF

eradication for primary prevention of gastric cancer: progresses and challenges.

J Natl Cancer Cent

December 2024

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.

Gastric cancer remains a significant global health challenge, causing a substantial number of cancer-related deaths, particularly in China. While the exact causes of gastric cancer are still being investigated, () infection has been identified as the primary risk factor, which triggers chronic inflammation and a multistage progression of gastric lesions that may lead to carcinogenesis over a long latency time. Since the 1990s, numerous efforts have focused on assessing the effectiveness of eradication in preventing new cases of gastric cancer among both the general population and patients who have undergone early-stage cancer treatment.

View Article and Find Full Text PDF

The spread of molecular markers of artemisinin partial resistance and diagnostic evasion in Eritrea: a retrospective molecular epidemiology study.

Lancet Microbe

December 2024

Drug Resistance and Diagnostics, Australian Defence Force Malaria and Infectious Disease Institute, Gallipolli Barracks, Enoggera, QLD, Australia; Australian Defence Force Malaria and Infectious Disease Institute Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. Electronic address:

Background: Eritrea was the first African country to discontinue the use of histidine rich protein 2 (HRP2)-detecting rapid diagnostic tests (RDTs) for malaria diagnosis following reports of a high prevalence of pfhrp2/3-deleted Plasmodium falciparum parasites causing false-negative results in the country. Eritrea was also the first African country to report partial artemisinin resistance due to the P falciparum kelch13 (pfk13) Arg622Ile mutation. We aimed to characterise the spatial distribution of pfk13 mutants and their interactions with pfhrp2/3 deletions in Eritrea and to assess the role of the use of HRP2-detecting RDTs and antimalarial (artesunate-amodiaquine) therapy in the spread of the two variants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!